Abstract
The tumor suppressor p53 is lost or mutated in approximately half of human cancers. Mutant p53 not only loses its anti-tumor transcriptional activity, but also often acquires oncogenic functions to promote tumor proliferation, invasion, and drug resistance. Traditional strategies have been taken to directly target p53 mutants through identifying small molecular compounds to deplete mutant p53, or to restore its tumor suppressive function. Accumulating evidence suggest that cancer cells with mutated p53 often exhibit specific functional dependencies on secondary genes or pathways to survive, providing alternative targets to indirectly treat p53-mutant cancers. Targeting these genes or pathways, critical for survival in the presence of p53 mutations, holds great promise for cancer treatment. In addition, mutant p53 often exhibits novel gain-of-functions to promote tumor growth and metastasis. Here, we review and discuss strategies targeting mutant p53, with focus on targeting the mutant p53 protein directly, and on the progress of identifying genes and pathways required in p53-mutant cells.
Similar content being viewed by others
References
Brown CJ, Lain S, Verma CS, Fersht AR, Lane DP (2009) Awakening guardian angels: drugging the p53 pathway. Nat Rev Cancer 9(12):862–873
Mandinova A, Lee SW (2011) The p53 pathway as a target in cancer therapeutics: obstacles and promise. Sci Transl Med 3(64):64rv1
Reinhardt HC, Schumacher B (2012) The p53 network: cellular and systemic DNA damage responses in aging and cancer. Trends Genet 28(3):128–136
Pellegata NS, Antoniono RJ, Redpath JL, Stanbridge EJ (1996) DNA damage and p53-mediated cell cycle arrest: a reevaluation. Proc Natl Acad Sci USA. 93(26):15209–15214
Hainaut P, Wiman KG (2009) 30 years and a long way into p53 research. Lancet Oncol. 10(9):913–919
Vousden KH, Lu X (2002) Live or let die: the cell’s response to p53. Nat Rev Cancer 2(8):594–604
Vazquez A, Bond EE, Levine AJ, Bond GL (2008) The genetics of the p53 pathway, apoptosis and cancer therapy. Nat Rev Drug Discov. 7(12):979–987
Muller PA, Vousden KH (2013) p53 mutations in cancer. Nat Cell Biol 15(1):2–8
Kandoth C, McLellan MD, Vandin F, Ye K, Niu B, Lu C, Xie M, Zhang Q, McMichael JF, Wyczalkowski MA et al (2013) Mutational landscape and significance across 12 major cancer types. Nature 502(7471):333–339
Muller PA, Vousden KH (2014) Mutant p53 in cancer: new functions and therapeutic opportunities. Cancer Cell 25(3):304–317
Gurpinar E, Vousden KH (2015) Hitting cancers’ weak spots: vulnerabilities imposed by p53 mutation. Trends Cell Biol 25(8):486–495
Kruiswijk F, Labuschagne CF, Vousden KH (2015) p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat Rev Mol Cell Biol 16(7):393–405
Gibbons DL, Byers LA, Kurie JM (2014) Smoking, p53 mutation, and lung cancer. Mol Cancer Res 12(1):3–13
Duffy MJ, Synnott NC, McGowan PM, Crown J, O’Connor D, Gallagher WM (2014) p53 as a target for the treatment of cancer. Cancer Treat Rev 40(10):1153–1160
Corney DC, Flesken-Nikitin A, Choi J, Nikitin AY (2008) Role of p53 and Rb in ovarian cancer. Adv Exp Med Biol 622:99–117
Freed-Pastor WA, Prives C (2012) Mutant p53: one name, many proteins. Genes Dev 26(12):1268–1286
Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M (2007) TP53 mutations in human cancers: functional selection and impact on cancer prognosis and outcomes. Oncogene 26(15):2157–2165
Olivier M, Hollstein M, Hainaut P (2010) TP53 mutations in human cancers: origins, consequences, and clinical use. Cold Spring Harb Perspect Biol. 2(1):a001008
Sigal A, Rotter V (2000) Oncogenic mutations of the p53 tumor suppressor: the demons of the guardian of the genome. Cancer Res 60(24):6788–6793
Cho Y, Gorina S, Jeffrey PD, Pavletich NP (1994) Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. Science 265(5170):346–355
Haupt S, Raghu D, Haupt Y (2016) Mutant p53 drives cancer by subverting multiple tumor suppression pathways. Front Oncol 6:12
Oren M, Rotter V (2010) Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2(2):a001107
Zhou G, Wang J, Zhao M, Xie TX, Tanaka N, Sano D, Patel AA, Ward AM, Sandulache VC, Jasser SA et al (2014) Gain-of-function mutant p53 promotes cell growth and cancer cell metabolism via inhibition of AMPK activation. Mol Cell 54(6):960–974
Lu X, Liu DP, Xu Y (2013) The gain of function of p53 cancer mutant in promoting mammary tumorigenesis. Oncogene 32(23):2900–2906
Sturm I, Bosanquet AG, Hermann S, Guner D, Dorken B, Daniel PT (2003) Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy. Cell Death Differ 10(4):477–484
Powell E, Piwnica-Worms D, Piwnica-Worms H (2014) Contribution of p53 to metastasis. Cancer Discov 4(4):405–414
Wischhusen J, Naumann U, Ohgaki H, Rastinejad F, Weller M (2003) CP-31398, a novel p53-stabilizing agent, induces p53-dependent and p53-independent glioma cell death. Oncogene 22(51):8233–8245
Foster BA, Coffey HA, Morin MJ, Rastinejad F (1999) Pharmacological rescue of mutant p53 conformation and function. Science 286(5449):2507–2510
Tang X, Zhu Y, Han L, Kim AL, Kopelovich L, Bickers DR, Athar M (2007) CP-31398 restores mutant p53 tumor suppressor function and inhibits UVB-induced skin carcinogenesis in mice. J Clin Invest 117(12):3753–3764
Weinmann L, Wischhusen J, Demma MJ, Naumann U, Roth P, Dasmahapatra B, Weller M (2008) A novel p53 rescue compound induces p53-dependent growth arrest and sensitises glioma cells to Apo2L/TRAIL-induced apoptosis. Cell Death Differ 15(4):718–729
Loh SN (2010) The missing zinc: p53 misfolding and cancer. Metallomics 2(7):442–449
Hainaut P, Mann K (2001) Zinc binding and redox control of p53 structure and function. Antioxid Redox Signal 3(4):611–623
Puca R, Nardinocchi L, Porru M, Simon AJ, Rechavi G, Leonetti C, Givol D, D’Orazi G (2011) Restoring p53 active conformation by zinc increases the response of mutant p53 tumor cells to anticancer drugs. Cell Cycle 10(10):1679–1689
Yu X, Vazquez A, Levine AJ, Carpizo DR (2012) Allele-specific p53 mutant reactivation. Cancer Cell 21(5):614–625
Joerger AC, Fersht AR (2010) The tumor suppressor p53: from structures to drug discovery. Cold Spring Harb Perspect Biol 2(6):a000919
Liu X, Wilcken R, Joerger AC, Chuckowree IS, Amin J, Spencer J, Fersht AR (2013) Small molecule induced reactivation of mutant p53 in cancer cells. Nucleic Acids Res 41(12):6034–6044
Hiraki M, Hwang SY, Cao S, Ramadhar TR, Byun S, Yoon KW, Lee JH, Chu K, Gurkar AU, Kolev V et al (2015) Small-Molecule Reactivation of Mutant p53 to Wild-Type-like p53 through the p53-Hsp40 Regulatory Axis. Chem Biol 22(9):1206–1216
Kung AL, Zabludoff SD, France DS, Freedman SJ, Tanner EA, Vieira A, Cornell-Kennon S, Lee J, Wang B, Wang J et al (2004) Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway. Cancer Cell 6(1):33–43
Gupta P, Srivastava SK (2012) Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models. BMC Med 10:80
Aggarwal M, Saxena R, Sinclair E, Fu Y, Jacobs A, Dyba M, Wang X, Cruz I, Berry D, Kallakury B et al (2016) Reactivation of mutant p53 by a dietary-related compound phenethyl isothiocyanate inhibits tumor growth. Cell Death Differ 23(10):1615–1627
Issaeva N, Bozko P, Enge M, Protopopova M, Verhoef LG, Masucci M, Pramanik A, Selivanova G (2004) Small molecule RITA binds to p53, blocks p53-HDM-2 interaction and activates p53 function in tumors. Nat Med 10(12):1321–1328
Zhao CY, Grinkevich VV, Nikulenkov F, Bao W, Selivanova G (2010) Rescue of the apoptotic-inducing function of mutant p53 by small molecule RITA. Cell Cycle 9(9):1847–1855
Burmakin M, Shi Y, Hedstrom E, Kogner P, Selivanova G (2013) Dual targeting of wild-type and mutant p53 by small molecule RITA results in the inhibition of N-Myc and key survival oncogenes and kills neuroblastoma cells in vivo and in vitro. Clin Cancer Res 19(18):5092–5103
Weilbacher A, Gutekunst M, Oren M, Aulitzky WE, van der Kuip H (2014) RITA can induce cell death in p53-defective cells independently of p53 function via activation of JNK/SAPK and p38. Cell Death Dis 5:e1318
Roh JL, Ko JH, Moon SJ, Ryu CH, Choi JY, Koch WM (2012) The p53-reactivating small-molecule RITA enhances cisplatin-induced cytotoxicity and apoptosis in head and neck cancer. Cancer Lett 325(1):35–41
Salim KY, Vareki SM, Danter WR, Koropatnick J (2016) COTI-2, a new anticancer drug currently under clinical investigation, targets mutant p53 and negatively modulates the PI3K/AKT/mTOR pathway. Eur J Cancer 69:S19
Salim KY, Vareki SM, Danter WR, Koropatnick J (2016) COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo. Oncotarget 7(27):41363–41379
Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Bergman J, Wiman KG, Selivanova G (2002) Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Nat Med 8(3):282–288
Lambert JM, Moshfegh A, Hainaut P, Wiman KG, Bykov VJ (2010) Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Oncogene 29(9):1329–1338
Lambert JM, Gorzov P, Veprintsev DB, Soderqvist M, Segerback D, Bergman J, Fersht AR, Hainaut P, Wiman KG, Bykov VJ (2009) PRIMA-1 reactivates mutant p53 by covalent binding to the core domain. Cancer Cell 15(5):376–388
Zandi R, Selivanova G, Christensen CL, Gerds TA, Willumsen BM, Poulsen HS (2011) PRIMA-1Met/APR-246 induces apoptosis and tumor growth delay in small cell lung cancer expressing mutant p53. Clin Cancer Res 17(9):2830–2841
Fransson A, Glaessgen D, Alfredsson J, Wiman KG, Bajalica-Lagercrantz S, Mohell N (2016) Strong synergy with APR-246 and DNA-damaging drugs in primary cancer cells from patients with TP53 mutant high-grade serous ovarian cancer. J Ovarian Res 9(1):27
Walerych D, Lisek K, Sommaggio R, Piazza S, Ciani Y, Dalla E, Rajkowska K, Gaweda-Walerych K, Ingallina E, Tonelli C et al (2016) Proteasome machinery is instrumental in a common gain-of-function program of the p53 missense mutants in cancer. Nat Cell Biol 18(8):897–909
Lehmann S, Bykov VJ, Ali D, Andren O, Cherif H, Tidefelt U, Uggla B, Yachnin J, Juliusson G, Moshfegh A et al (2012) Targeting p53 in vivo: a first-in-human study with p53-targeting compound APR-246 in refractory hematologic malignancies and prostate cancer. J Clin Oncol 30(29):3633–3639
Singer G, Stohr R, Cope L, Dehari R, Hartmann A, Cao DF, Wang TL, Kurman RJ, Shih Ie M (2005) Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation. Am J Surg Pathol 29(2):218–224
Li D, Marchenko ND, Moll UM (2011) SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis. Cell Death Differ 18(12):1904–1913
Li D, Marchenko ND, Schulz R, Fischer V, Velasco-Hernandez T, Talos F, Moll UM (2011) Functional inactivation of endogenous MDM2 and CHIP by HSP90 causes aberrant stabilization of mutant p53 in human cancer cells. Mol Cancer Res 9(5):577–588
Alexandrova EM, Yallowitz AR, Li D, Xu S, Schulz R, Proia DA, Lozano G, Dobbelstein M, Moll UM (2015) Improving survival by exploiting tumour dependence on stabilized mutant p53 for treatment. Nature 523(7560):352–356
Jhaveri K, Modi S (2015) Ganetespib: research and clinical development. Onco Targets Ther 8:1849–1858
Lippi G, Plebani M (2017) Statins for primary prevention of cardiovascular disease. Trends Pharmacol Sci 38(2):111–112
Parrales A, Ranjan A, Iyer SV, Padhye S, Weir SJ, Roy A, Iwakuma T (2016) DNAJA1 controls the fate of misfolded mutant p53 through the mevalonate pathway. Nature Cell Biol 18(11):1233
Martirosyan A, Clendening JW, Goard CA, Penn LZ (2010) Lovastatin induces apoptosis of ovarian cancer cells and synergizes with doxorubicin: potential therapeutic relevance. BMC Cancer 10:103
Gu H, Wang X, Rao S, Wang J, Zhao J, Ren FL, Mu R, Yang Y, Qi Q, Liu W et al (2008) Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells. Mol Cancer Ther 7(10):3298–3305
Wang J, Zhao Q, Qi Q, Gu HY, Rong JJ, Mu R, Zou MJ, Tao L, You QD, Guo QL (2011) Gambogic acid-induced degradation of mutant p53 is mediated by proteasome and related to CHIP. J Cell Biochem 112(2):509–519
Foggetti G, Ottaggio L, Russo D, Monti P, Degan P, Fronza G, Menichini P (2016) Gambogic acid counteracts mutant p53 stability by inducing autophagy. Biochim Biophys Acta 1864(2):382–392
Yi YW, Kang HJ, Kim HJ, Kong Y, Brown ML, Bae I (2013) Targeting mutant p53 by a SIRT1 activator YK-3-237 inhibits the proliferation of triple-negative breast cancer cells. Oncotarget 4(7):984–994
Garufi A, Pistritto G, Cirone M, D’Orazi G (2016) Reactivation of mutant p53 by capsaicin, the major constituent of peppers. J Exp Clin Cancer Res 35(1):136
Dobzhansky T (1946) Genetics of Natural Populations. Xiii. Recombination and Variability in Populations of Drosophila Pseudoobscura. Genetics 31(3):269–290
Lord CJ, Tutt AN, Ashworth A (2015) Synthetic lethality and cancer therapy: lessons learned from the development of PARP inhibitors. Annu Rev Med 66:455–470
de la Fece Cruz F, Gapp BV, Nijman SM (2015) Synthetic lethal vulnerabilities of cancer. Annu Rev Pharmacol Toxicol 55:513–531
McLornan DP, List A, Mufti GJ (2014) Applying synthetic lethality for the selective targeting of cancer. N Engl J Med 371(18):1725–1735
Garber K (2002) Synthetic lethality: killing cancer with cancer. J Natl Cancer Inst 94(22):1666–1668
Weidle UH, Maisel D, Eick D (2011) Synthetic lethality-based targets for discovery of new cancer therapeutics. Cancer Genom Proteom 8(4):159–171
Reinhardt HC, Jiang H, Hemann MT, Yaffe MB (2009) Exploiting synthetic lethal interactions for targeted cancer therapy. Cell Cycle 8(19):3112–3119
Kawabe T (2004) G2 checkpoint abrogators as anticancer drugs. Mol Cancer Ther 3(4):513–519
Koniaras K, Cuddihy AR, Christopoulos H, Hogg A, O’Connell MJ (2001) Inhibition of Chk1-dependent G2 DNA damage checkpoint radiosensitizes p53 mutant human cells. Oncogene 20(51):7453–7463
Smith J, Tho LM, Xu N, Gillespie DA (2010) The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv Cancer Res 108:73–112
Bartek J, Lukas J (2003) Chk1 and Chk2 kinases in checkpoint control and cancer. Cancer Cell 3(5):421–429
Furusawa Y, Iizumi T, Fujiwara Y, Zhao QL, Tabuchi Y, Nomura T, Kondo T (2012) Inhibition of checkpoint kinase 1 abrogates G2/M checkpoint activation and promotes apoptosis under heat stress. Apoptosis 17(1):102–112
Yu H (2007) Chk1: a double agent in cell cycle checkpoints. Dev Cell 12(2):167–168
Origanti S, Cai SR, Munir AZ, White LS, Piwnica-Worms H (2013) Synthetic lethality of Chk1 inhibition combined with p53 and/or p21 loss during a DNA damage response in normal and tumor cells. Oncogene 32(5):577–588
Toledo LI, Murga M, Zur R, Soria R, Rodriguez A, Martinez S, Oyarzabal J, Pastor J, Bischoff JR, Fernandez-Capetillo O (2011) A cell-based screen identifies ATR inhibitors with synthetic lethal properties for cancer-associated mutations. Nat Struct Mol Biol 18(6):721–727
Ma CX, Janetka JW, Piwnica-Worms H (2011) Death by releasing the breaks: cHK1 inhibitors as cancer therapeutics. Trends Mol Med 17(2):88–96
Ma CX, Ellis MJ, Petroni GR, Guo Z, Cai SR, Ryan CE, Craig Lockhart A, Naughton MJ, Pluard TJ, Brenin CM et al (2013) A phase II study of UCN-01 in combination with irinotecan in patients with metastatic triple negative breast cancer. Breast Cancer Res Treat 137(2):483–492
Fracasso PM, Williams KJ, Chen RC, Picus J, Ma CX, Ellis MJ, Tan BR, Pluard TJ, Adkins DR, Naughton MJ et al (2011) A Phase 1 study of UCN-01 in combination with irinotecan in patients with resistant solid tumor malignancies. Cancer Chemother Pharmacol 67(6):1225–1237
Lapenna S, Giordano A (2009) Cell cycle kinases as therapeutic targets for cancer. Nat Rev Drug Discov. 8(7):547–566
Chen Z, Xiao Z, Gu WZ, Xue J, Bui MH, Kovar P, Li G, Wang G, Tao ZF, Tong Y et al (2006) Selective Chk1 inhibitors differentially sensitize p53-deficient cancer cells to cancer therapeutics. Int J Cancer 119(12):2784–2794
Ma CX, Cai S, Li S, Ryan CE, Guo Z, Schaiff WT, Lin L, Hoog J, Goiffon RJ, Prat A et al (2012) Targeting Chk1 in p53-deficient triple-negative breast cancer is therapeutically beneficial in human-in-mouse tumor models. J Clin Invest 122(4):1541–1552
Gadhikar MA, Sciuto MR, Alves MV, Pickering CR, Osman AA, Neskey DM, Zhao M, Fitzgerald AL, Myers JN, Frederick MJ (2013) Chk1/2 inhibition overcomes the cisplatin resistance of head and neck cancer cells secondary to the loss of functional p53. Mol Cancer Ther 12(9):1860–1873
Manke IA, Nguyen A, Lim D, Stewart MQ, Elia AE, Yaffe MB (2005) MAPKAP kinase-2 is a cell cycle checkpoint kinase that regulates the G2/M transition and S phase progression in response to UV irradiation. Mol Cell 17(1):37–48
Reinhardt HC, Aslanian AS, Lees JA, Yaffe MB (2007) p53-deficient cells rely on ATM- and ATR-mediated checkpoint signaling through the p38MAPK/MK2 pathway for survival after DNA damage. Cancer Cell 11(2):175–189
Morandell S, Reinhardt HC, Cannell IG, Kim JS, Ruf DM, Mitra T, Couvillon AD, Jacks T, Yaffe MB (2013) A reversible gene-targeting strategy identifies synthetic lethal interactions between MK2 and p53 in the DNA damage response in vivo. Cell Rep 5(4):868–877
Zitouni S, Nabais C, Jana SC, Guerrero A, Bettencourt-Dias M (2014) Polo-like kinases: structural variations lead to multiple functions. Nat Rev Mol Cell Biol 15(7):433–452
Sur S, Pagliarini R, Bunz F, Rago C, Diaz LA Jr, Kinzler KW, Vogelstein B, Papadopoulos N (2009) A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci USA 106(10):3964–3969
Yim H (2013) Current clinical trials with polo-like kinase 1 inhibitors in solid tumors. Anticancer Drugs 24(10):999–1006
Degenhardt Y, Greshock J, Laquerre S, Gilmartin AG, Jing J, Richter M, Zhang X, Bleam M, Halsey W, Hughes A et al (2010) Sensitivity of cancer cells to Plk1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol Cancer Ther 9(7):2079–2089
O’Connell MJ, Raleigh JM, Verkade HM, Nurse P (1997) Chk1 is a wee1 kinase in the G2 DNA damage checkpoint inhibiting cdc2 by Y15 phosphorylation. EMBO J 16(3):545–554
Vera J, Raatz Y, Wolkenhauer O, Kottek T, Bhattacharya A, Simon JC, Kunz M (2015) Chk1 and Wee1 control genotoxic-stress induced G2-M arrest in melanoma cells. Cell Signal 27(5):951–960
Moser R, Xu C, Kao M, Annis J, Lerma LA, Schaupp CM, Gurley KE, Jang IS, Biktasova A, Yarbrough WG et al (2014) Functional kinomics identifies candidate therapeutic targets in head and neck cancer. Clin Cancer Res 20(16):4274–4288
Osman AA, Monroe MM, Ortega Alves MV, Patel AA, Katsonis P, Fitzgerald AL, Neskey DM, Frederick MJ, Woo SH, Caulin C et al (2015) Wee-1 kinase inhibition overcomes cisplatin resistance associated with high-risk TP53 mutations in head and neck cancer through mitotic arrest followed by senescence. Mol Cancer Ther 14(2):608–619
Brana I, Moore KN, Shapira-Frommer R, Welch S, Jou YM, Marinucci M, Freshwater T, Rose S, and Oza AM (2013) Targeting p53 mutant ovarian cancer: Phase I results of the WEE1 inhibitor MK-1775 with carboplatin plus paclitaxel in patients (pts) with platinum-sensitive, p53-mutant ovarian cancer (OC). J Clin Oncol 31(15_suppl):5518. doi:10.1200/jco.2013.31.15_suppl.5518
Baldwin A, Grueneberg DA, Hellner K, Sawyer J, Grace M, Li WL, Harlow E, Munger K (2010) Kinase requirements in human cells: V. Synthetic lethal interactions between p53 and the protein kinases SGK2 and PAK3. P Natl Acad Sci USA 107(28):12463–12468
Winey M, Huneycutt BJ (2002) Centrosomes and checkpoints: the MPS1 family of kinases. Oncogene 21(40):6161–6169
Foley EA, Kapoor TM (2013) Microtubule attachment and spindle assembly checkpoint signalling at the kinetochore. Nat Rev Mol Cell Bio. 14(1):25–37
London N, Biggins S (2014) Signalling dynamics in the spindle checkpoint response. Nat Rev Mol Cell Bio. 15(11):735–747
Jemaa M, Galluzzi L, Kepp O, Boileve A, Lissa D, Senovilla L, Harper F, Pierron G, Berardinelli F, Antoccia A et al (2012) Preferential killing of p53-deficient cancer cells by reversine. Cell Cycle 11(11):2149–2158
Gyorffy B, Bottai G, Lehmann-Che J, Keri G, Orfi L, Iwamoto T, Desmedt C, Bianchini G, Turner NC, de The H et al (2014) TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancers. Mol Oncol 8(3):508–519
Olovnikov IA, Kravchenko JE, Chumakov PM (2009) Homeostatic functions of the p53 tumor suppressor: regulation of energy metabolism and antioxidant defense. Semin Cancer Biol 19(1):32–41
Berkers CR, Maddocks OD, Cheung EC, Mor I, Vousden KH (2013) Metabolic regulation by p53 family members. Cell Metab 18(5):617–633
Emerling BM, Hurov JB, Poulogiannis G, Tsukazawa KS, Choo-Wing R, Wulf GM, Bell EL, Shim HS, Lamia KA, Rameh LE et al (2013) Depletion of a putatively druggable class of phosphatidylinositol kinases inhibits growth of p53-null tumors. Cell 155(4):844–857
Lokody I (2014) Signalling: a new target for p53-null tumours. Nat Rev Cancer 14(1):8–9
Wang L, Xiong H, Wu FX, Zhang YJ, Wang J, Zhao LY, Guo XL, Chang LJ, Zhang Y, You MJ et al (2014) Hexokinase 2-mediated warburg effect is required for PTEN- and p53-deficiency-driven prostate cancer growth. Cell Rep 8(5):1461–1474
Tan VP, Miyamoto S (2015) HK2/hexokinase-II integrates glycolysis and autophagy to confer cellular protection. Autophagy 11(6):963–964
Wolf A, Agnihotri S, Micallef J, Mukherjee J, Sabha N, Cairns R, Hawkins C, Guha A (2011) Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiforme. J Exp Med 208(2):313–326
Wagner EF, Nebreda AR (2009) Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer 9(8):537–549
Hui L, Bakiri L, Mairhorfer A, Schweifer N, Haslinger C, Kenner L, Komnenovic V, Scheuch H, Beug H, Wagner EF (2007) p38alpha suppresses normal and cancer cell proliferation by antagonizing the JNK-c-Jun pathway. Nat Genet 39(6):741–749
Dolado I, Swat A, Ajenjo N, De Vita G, Cuadrado A, Nebreda AR (2007) p38alpha MAP kinase as a sensor of reactive oxygen species in tumorigenesis. Cancer Cell 11(2):191–205
Merlin JL, Harle A, Lion M, Ramacci C, Leroux A (2013) Expression and activation of P38 MAP kinase in invasive ductal breast cancers: correlation with expression of the estrogen receptor, HER2 and downstream signaling phosphorylated proteins. Oncol Rep 30(4):1943–1948
Wang SN, Lee KT, Tsai CJ, Chen YJ, Yeh YT (2012) Phosphorylated p38 and JNK MAPK proteins in hepatocellular carcinoma. Eur J Clin Invest 42(12):1295–1301
Chen L, Mayer JA, Krisko TI, Speers CW, Wang T, Hilsenbeck SG, Brown PH (2009) Inhibition of the p38 kinase suppresses the proliferation of human ER-negative breast cancer cells. Cancer Res 69(23):8853–8861
Pereira L, Igea A, Canovas B, Dolado I, Nebreda AR (2013) Inhibition of p38 MAPK sensitizes tumour cells to cisplatin-induced apoptosis mediated by reactive oxygen species and JNK. EMBO Mol Med 5(11):1759–1774
Cohen O, Inbal B, Kissil JL, Raveh T, Berissi H, Spivak-Kroizaman T, Feinstein E, Kimchi A (1999) DAP-kinase participates in TNF-alpha- and Fas-induced apoptosis and its function requires the death domain. J Cell Biol 146(1):141–148
Jang CW, Chen CH, Chen CC, Chen JY, Su YH, Chen RH (2002) TGF-beta induces apoptosis through Smad-mediated expression of DAP-kinase. Nat Cell Biol 4(1):51–58
Deiss LP, Feinstein E, Berissi H, Cohen O, Kimchi A (1995) Identification of a novel serine threonine kinase and a novel 15-Kd protein as potential mediators of the gamma-interferon-induced cell-death. Gene Dev 9(1):15–30
Zhao J, Zhao DK, Poage GM, Mazumdar A, Zhang Y, Hill JL, Hartman ZC, Savage MI, Mills GB, Brown PH (2015) Death-associated protein kinase 1 promotes growth of p53-mutant cancers. J Clin Invest 125(7):2707–2720
Rakoff-Nahoum S, Medzhitov R (2009) Toll-like receptors and cancer. Nat Rev Cancer 9(1):57–63
Xu H, Yan J, Zhu ZQ, Hussain LR, Huang YM, Wen YJ, Ildstad ST (2010) A critical role of innate immunity via TLR4 signaling via the trif pathway in allogeneic bone marrow cell rejection. Am J Transplant 10:99
Rajput S, Volk-Draper LD, Ran S (2013) TLR4 Is a novel determinant of the response to paclitaxel in breast cancer. Mol Cancer Ther 12(8):1676–1687
Haricharan S, Brown P (2015) TLR4 has a TP53-dependent dual role in regulating breast cancer cell growth. P Natl Acad Sci USA 112(25):E3216–E3225
Shatz M, Menendez D, Resnick MA (2012) The human TLR innate immune gene family is differentially influenced by dna stress and p53 status in cancer cells. Can Res 72(16):3948–3957
Menendez D, Lowe JM, Snipe J, Resnick MA (2016) Ligand dependent restoration of human TLR3 signaling and death in p53 mutant cells. Oncotarget 7(38):61630–61642
Hainaut P, Pfeifer GP (2016) Somatic TP53 mutations in the era of genome sequencing. Cold Spring Harb Perspect Med 6(11):a02179
Glick D, Barth S, Macleod KF (2010) Autophagy: cellular and molecular mechanisms. J Pathol 221(1):3–12
White E (2015) The role for autophagy in cancer. J Clin Invest 125(1):42–46
Xie XL, Le L, Fan YX, Lv L, Zhang JJ (2012) Autophagy is induced through the ROS-TP53-DRAM1 pathway in response to mitochondrial protein synthesis inhibition. Autophagy 8(7):1071–1084
Dando I, Cordani M, Donadelli M (2016) Mutant p53 and mTOR/PKM2 regulation in cancer cells. IUBMB Life 68(9):722–726
Cordani M, Oppici E, Dando I, Butturini E, Pozza ED, Nadal-Serrano M, Oliver J, Roca P, Mariotto S, Cellini B et al (2016) Mutant p53 proteins counteract autophagic mechanism sensitizing cancer cells to mTOR inhibition. Mol Oncol 10(7):1008–1029
Morselli E, Tasdemir E, Maiuri MC, Galluzzi L, Kepp O, Criollo A, Vicencio JM, Soussi T, Kroemer G (2014) Mutant p53 protein localized in the cytoplasm inhibits autophagy (vol 7, pg 3056, 2008). Cell Cycle 13(14):2311
Kim J, Kundu M, Viollet B, Guan KL (2011) AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1. Nat Cell Biol 13(2):132-U71
Heiden MGV, Cantley LC, Thompson CB (2009) Understanding the warburg effect: the metabolic requirements of cell proliferation. Science 324(5930):1029–1033
Zhang C, Liu J, Liang YJ, Wu R, Zhao YH, Hong XH, Lin MH, Yu HY, Liu LX, Levine AJ et al (2013) Tumour-associated mutant p53 drives the Warburg effect. Nat Commun 4
Timpson P, McGhee EJ, Morton JP, von Kriegsheim A, Schwarz JP, Karim SA, Doyle B, Quinn JA, Carragher NO, Edward M et al (2011) Spatial regulation of RhoA Activity during pancreatic cancer cell invasion driven by mutant p53. Can Res 71(3):747–757
Muller PAJ, Caswell PT, Doyle B, Iwanicki MP, Tan EH, Karim S, Lukashchuk N, Gillespie DA, Ludwig RL, Gosselin P et al (2009) Mutant p53 drives invasion by promoting integrin recycling. Cell 139(7):1327–1341
Steller EJ, Raats DA, Koster J, Rutten B, Govaert KM, Emmink BL, Snoeren N, van Hooff SR, Holstege FC, Maas C et al (2013) PDGFRB promotes liver metastasis formation of mesenchymal-like colorectal tumor cells. Neoplasia 15(2):204–217
Jechlinger M, Sommer A, Moriggl R, Seither P, Kraut N, Capodiecci P, Donovan M, Cordon-Cardo C, Beug H, Grunert S (2006) Autocrine PDGFR signaling promotes mammary cancer metastasis. J Clin Invest 116(6):1561–1570
Weissmueller S, Manchado E, Saborowski M, Morris JPT, Wagenblast E, Davis CA, Moon SH, Pfister NT, Tschaharganeh DF, Kitzing T et al (2014) Mutant p53 drives pancreatic cancer metastasis through cell-autonomous PDGF receptor beta signaling. Cell 157(2):382–394
Xiong S, Tu H, Kollareddy M, Pant V, Li Q, Zhang Y, Jackson JG, Suh YA, Elizondo-Fraire AC, Yang P et al (2014) Pla2g16 phospholipase mediates gain-of-function activities of mutant p53. Proc Natl Acad Sci USA 111(30):11145–11150
Freed-Pastor WA, Mizuno H, Zhao X, Langerod A, Moon SH, Rodriguez-Barrueco R, Barsotti A, Chicas A, Li WC, Polotskaia A et al (2012) Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 148(1–2):244–258
Alderton GK (2012) Morphology Oncogenic morphs of p53. Nature Rev Cancer 12(3)
Kollareddy M, Dimitrova E, Vallabhaneni KC, Chan A, Le T, Chauhan KM, Carrero ZI, Ramakrishnan G, Watabe K, Haupt Y et al (2015) Regulation of nucleotide metabolism by mutant p53 contributes to its gain-of-function activities. Nature Commun 6
Zhou G, Myers JN (2014) Mutant p53 exerts oncogenic functions by modulating cancer cell metabolism. Mol Cell Oncol 1(3):e963441
Feng ZH, Hu WW, de Stanchina E, Teresky AK, Jin SK, Lowe S, Levine AJ (2007) The regulation of AMPK beta 1, TSC2, and PTEN expression by p53: stress, cell and tissue specificity, and the role of these gene products in modulating the IGF-1-AKT-mTOR pathways. Can Res 67(7):3043–3053
Zhu J, Sammons MA, Donahue G, Dou Z, Vedadi M, Getlik M, Barsyte-Lovejoy D, Al-awar R, Katona BW, Shilatifard A et al (2015) Gain-of-function p53 mutants co-opt chromatin pathways to drive cancer growth. Nature 525(7568):206–211
Prives C, Lowe SW (2015) Cancer: mutant p53 and chromatin regulation. Nature 525(7568):199–200
Pfister NT, Fomin V, Regunath K, Zhou JY, Zhou W, Silwal-Pandit L, Freed-Pastor WA, Laptenko O, Neo SP, Bargonetti J et al (2015) Mutant p53 cooperates with the SWI/SNF chromatin remodeling complex to regulate VEGFR2 in breast cancer cells. Genes Dev 29(12):1298–1315
Parrales A, Iwakuma T (2015) Targeting oncogenic mutant p53 for cancer therapy. Front Oncol 5:288
Reles A, Wen WH, Schmider A, Gee C, Runnebaum IB, Kilian U, Jones LA, El-Naggar A, Minguillon C, Schonborn I et al (2001) Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer. Clin Cancer Res 7(10):2984–2997
Chan KT, Lung ML (2004) Mutant p53 expression enhances drug resistance in a hepatocellular carcinoma cell line. Cancer Chemother Pharmacol 53(6):519–526
Wong RP, Tsang WP, Chau PY, Co NN, Tsang TY, Kwok TT (2007) p53-R273H gains new function in induction of drug resistance through down-regulation of procaspase-3. Mol Cancer Ther 6(3):1054–1061
Do PM, Varanasi L, Fan S, Li C, Kubacka I, Newman V, Chauhan K, Daniels SR, Boccetta M, Garrett MR et al (2012) Mutant p53 cooperates with ETS2 to promote etoposide resistance. Genes Dev 26(8):830–845
Fiorini C, Cordani M, Padroni C, Blandino G, Di Agostino S, Donadelli M (2015) Mutant p53 stimulates chemoresistance of pancreatic adenocarcinoma cells to gemcitabine. Bba-Mol Cell Res 1853(1):89–100
Acknowledgements
We would like to thank Sam Short for her assistance with this submission.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Financial support
This work was funded by a Komen SAB grant (P.H.B.), a Breast Cancer Research Foundation grant (P.H.B.), a John Charles Cain Distinguished Chair Award (P.H.B.), a John F. and Julie Young Award (P.H.B.), and a Cancer Center Support Grant (5 P30 CA016672-38 P.H.B.).
Conflict of interest
PH Brown is on the Scientific Advisory Board of Susan G. Komen for the Cure. All remaining authors declare no actual, potential, or perceived conflict of interest that would prejudice the impartiality of this article.
Rights and permissions
About this article
Cite this article
Zhao, D., Tahaney, W.M., Mazumdar, A. et al. Molecularly targeted therapies for p53-mutant cancers. Cell. Mol. Life Sci. 74, 4171–4187 (2017). https://doi.org/10.1007/s00018-017-2575-0
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00018-017-2575-0